530 related articles for article (PubMed ID: 28592566)
1. Combined immune checkpoint blockade as a therapeutic strategy for
Nolan E; Savas P; Policheni AN; Darcy PK; Vaillant F; Mintoff CP; Dushyanthen S; Mansour M; Pang JB; Fox SB; ; Perou CM; Visvader JE; Gray DHD; Loi S; Lindeman GJ
Sci Transl Med; 2017 Jun; 9(393):. PubMed ID: 28592566
[TBL] [Abstract][Full Text] [Related]
2. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
4. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
Wen WX; Leong CO
PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
6. Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.
Green AR; Aleskandarany MA; Ali R; Hodgson EG; Atabani S; De Souza K; Rakha EA; Ellis IO; Madhusudan S
Cancer Immunol Res; 2017 Apr; 5(4):292-299. PubMed ID: 28254786
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
8. Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer.
Kraya AA; Maxwell KN; Wubbenhorst B; Wenz BM; Pluta J; Rech AJ; Dorfman LM; Lunceford N; Barrett A; Mitra N; Morrissette JJD; Feldman M; Nayak A; Domchek SM; Vonderheide RH; Nathanson KL
Clin Cancer Res; 2019 Jul; 25(14):4363-4374. PubMed ID: 30914433
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.
Engel JB; Honig A; Kapp M; Hahne JC; Meyer SR; Dietl J; Segerer SE
Arch Gynecol Obstet; 2014 Jan; 289(1):141-7. PubMed ID: 23828443
[TBL] [Abstract][Full Text] [Related]
10. Doubling Down on BRCA-Mutated Cancer.
Wahner Hendrickson AE; Kaufmann SH; Swisher EM
Trends Cancer; 2017 Nov; 3(11):743-744. PubMed ID: 29120748
[TBL] [Abstract][Full Text] [Related]
11. BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.
Solinas C; Marcoux D; Garaud S; Vitória JR; Van den Eynden G; de Wind A; De Silva P; Boisson A; Craciun L; Larsimont D; Piccart-Gebhart M; Detours V; t'Kint de Roodenbeke D; Willard-Gallo K
Cancer Lett; 2019 May; 450():88-97. PubMed ID: 30797818
[TBL] [Abstract][Full Text] [Related]
12. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
[TBL] [Abstract][Full Text] [Related]
13. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
14. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
[TBL] [Abstract][Full Text] [Related]
15. Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.
Markosyan N; Chen EP; Evans RA; Ndong V; Vonderheide RH; Smyth EM
Breast Cancer Res; 2013; 15(5):R75. PubMed ID: 24004819
[TBL] [Abstract][Full Text] [Related]
16. Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.
El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
Mol Carcinog; 2017 May; 56(5):1383-1394. PubMed ID: 27864890
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.
Glodzik D; Bosch A; Hartman J; Aine M; Vallon-Christersson J; Reuterswärd C; Karlsson A; Mitra S; Niméus E; Holm K; Häkkinen J; Hegardt C; Saal LH; Larsson C; Malmberg M; Rydén L; Ehinger A; Loman N; Kvist A; Ehrencrona H; Nik-Zainal S; Borg Å; Staaf J
Nat Commun; 2020 Jul; 11(1):3747. PubMed ID: 32719340
[TBL] [Abstract][Full Text] [Related]
18. Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.
Taylor NA; Vick SC; Iglesia MD; Brickey WJ; Midkiff BR; McKinnon KP; Reisdorf S; Anders CK; Carey LA; Parker JS; Perou CM; Vincent BG; Serody JS
J Clin Invest; 2017 Sep; 127(9):3472-3483. PubMed ID: 28825599
[TBL] [Abstract][Full Text] [Related]
19. βhCG mediates immune suppression through upregulation of CD11b
Varghese GR; Patra D; Jaikumar VS; Rajan A; Latha NR; Srinivas P
Immunology; 2023 Oct; 170(2):270-285. PubMed ID: 37340549
[TBL] [Abstract][Full Text] [Related]
20. Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells.
Alvarado-Cruz I; Mahmoud M; Khan M; Zhao S; Oeck S; Meas R; Clairmont K; Quintana V; Zhu Y; Porciuncula A; Wyatt H; Ma S; Shyr Y; Kong Y; LoRusso PM; Laverty D; Nagel ZD; Schalper KA; Krauthammer M; Sweasy JB
Biochem Pharmacol; 2021 Feb; 184():114359. PubMed ID: 33285109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
